Hypothesis

Senolytic activity of quercetin requires not only sufficient plasma exposure but also a cellular environment where mTOR signaling is low, i.e., a famine‑mimic state. Under low mTOR, quercetin‑mediated BCL‑2 family inhibition synergizes with AMPK‑driven autophagy to push senescent cells past the apoptotic threshold. Therefore, sustained quercetin phytosome will clear senescent cells effectively only when mTOR activity is pharmacologically or nutritionally suppressed; isoquercetin’s brief spike will fail even with mTOR inhibition because the exposure time is insufficient.

Rationale

• Quercetin phytosome yields 7‑15‑fold higher AUC versus standard quercetin, maintaining detectable levels for >72 h (Quercetin phytosome PK).
• Isoquercetin is absorbed rapidly but cleared within ~45 min, giving a 150‑fold lower AUC than quercetin aglycone (Isoquercetin PK).
• mTOR inhibition (e.g., rapamycin) extends lifespan by simulating nutrient scarcity, activating autophagy and altering BCL‑2 family protein balance.
• Senolytic quercetin acts by inhibiting anti‑apoptotic BCL‑2/xL and MCL‑1, a process that is potentiated when pro‑autophagic signals are high and cellular energy stress is sensed via AMPK.
• Thus, the pharmacokinetic profile of quercetin must overlap temporally with a low‑mTOR, high‑AMPK state to achieve synergistic senescent cell clearance.

Predictions

1. In humans, quercetin phytosome combined with intermittent rapamycin dosing (or time‑restricted feeding) will produce greater reductions in SASP biomarkers (IL‑6, IL‑8, MMP‑9) than either agent alone.
2. Isoquercetin, even when paired with mTOR suppression, will not significantly lower senescent cell burden because its exposure window is too short to sustain BCL‑2 inhibition during the low‑mTOR phase.
3. The magnitude of senescent cell decline will correlate with the area under the curve of quercetin plasma concentration only during periods when phosphorylated‑S6K (a readout of mTOR activity) falls below a predefined threshold.

Experimental Design

• Study type: Randomized, double‑blind, crossover trial in healthy older adults (n = 30).
• Arms: (A) Quercetin phytosome 500 mg daily; (B) Placebo; (C) Quercetin phytosome + rapamycin 1 mg twice weekly; (D) Quercetin phytosome + time‑restricted feeding (8‑h window); (E) Isoquercetin 500 mg daily + rapamycin; (F) Isoquercetin 500 mg daily alone.
• Duration: 4‑week treatment periods with 2‑week washout.
• Sampling: Serial blood draws for quercetin/plasma levels (0‑72 h post‑dose), p‑S6K, p‑AMPK, SASP cytokines, and circulating senescent cell markers (e.g., cdkn2a‑p16 mRNA in extracellular vesicles) at baseline, 24 h, 48 h, and 72 h after each dose.
• Endpoints: Change from baseline in SASP composite score and senescent cell marker abundance.

Potential Outcomes

• If hypothesis is correct, arms C and D will show a statistically significant SASP reduction (>30 % vs baseline) correlated with quercetin AUC during low‑p‑S6K windows, whereas arm A will show modest change and arms B, E, F will show negligible effect.
• Failure to observe synergy would falsify the premise that mTOR‑low state is required for quercetin senolytic action, suggesting that plasma exposure alone suffices.

This framework directly ties quercetin pharmacokinetics to nutrient‑sensing signaling, offering a testable, falsifiable path forward for senolytic formulation development.